Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Resources>Webcasts>This Webcast
  Webcasts

Discovery Chemistry Outsourcing: Optimising the Process

Luigi LaVecchia, Director, Global Discovery Chemistry, Novartis speaking at Pharma Outsourcing Congress 2011
Date Posted: Tuesday, November 01, 2011

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Related Content

Novartis Receives EU Approval for Farydak®
Farydak (panobinostat) combination is approved in the EU for patients with multiple myeloma who received >=2 prior regimens including bortezomib and IMiD.
Tuesday, September 08, 2015
EU Approval For Tafinlar® and Mekinist®
Novartis have announced that the European Commission has approved the combination of Tafinlar® (dabrafenib) and Mekinist® (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Friday, September 04, 2015
Novartis, Amgen Partner
The companies plan to co-develop and co-commercialize a BACE inhibitor program in Alzheimer's Disease (AD); Novartis' oral therapy CNP520 will be the lead molecule.
Friday, September 04, 2015
FDA Expands Use of Novartis Drug Promacta®
New oral suspension formulation, designed for younger children with rare blood disorder, is now approved.
Wednesday, August 26, 2015
EU Approves Novartis's laBCC Therapy
Novartis has announced that the European Commission has approved Odomzo® 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) who are not amenable to curative surgery or radiation therapy.
Monday, August 24, 2015
Novartis Drug Odomzo® Gains EU Approval
Approval follows positive CHMP opinion based on pivotal Phase II study showing durable objective response rate per central review of 56% in patients with laBCC.
Friday, August 21, 2015
Novartis Acquires Spinifex Pharmaceuticals, Inc.
Acquisition adds novel angiotensin II Type 2 receptor antagonist for the treatment of neuropathic pain to Novartis' industry-leading development pipeline.
Monday, June 29, 2015
Novartis Announces Clinical Collaboration with Bristol-Myers Squibb
Collaboration highlights promising new treatment approach for patients and underscores Novartis' commitment to patients and the lung cancer community.
Tuesday, October 07, 2014
Novartis Gains Rights to Two Oral Targeted Investigational Therapies
Ex-US rights acquired for JAK inhibitor INCB18424 in Phase III development as first-in-class treatment for a life-threatening blood disorder.
Tuesday, December 01, 2009
New Data Show Zometa® Enhances Impact of Chemotherapy on Reducing Breast Tumor Size
Adding Zometa to chemotherapy prior to surgery led to an additional 33% reduction in tumor size, resulting in fewer mastectomies.
Monday, December 15, 2008
Scientific News
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
New Treatment for Immune Cancers
Clinical trial shows new drug holds promise for treating advanced mastocytosis.
Sickle Cell Gene Therapy Passes Test
Researchers found a precision-engineered gene therapy virus reduced sickle-induced red-cell damage in mice with sickle cell disease.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Stem Cell Therapy Heals Injured Mouse Brain
A team of researchers has developed a therapeutic technique that dramatically increases the production of nerve cells in mice with stroke-induced brain damage.
Zika Vaccine Testing in Humans
The NAAID has initiated a clinical trail of a vaccine candidate for the prevention of the Zika virus infection.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!